PLACE AND DATE OF
SEES PATIENTS AT:
Thomas Jefferson University
Enrolled in a five year BS/MD program with Pennsylvania State University and Thomas Jefferson University, Jefferson Medical College, June 1968. (Completed undergraduate degree requirements and four years of medical school in five calendar years.) Studies started at Pennsylvania State University and continued through August 1969. Began medical school at Jefferson Medical College, September 1969. Returned to Pennsylvania State University the summer of 1970 and graduated in absentia from Pennsylvania State University, September 1971 with honors. Graduated from Thomas Jefferson University/Jefferson Medical College of Philadelphia, June 1973.
INTERNSHIP AND RESIDENCY:
Residency in Neurology, January 1976 through June
HOSPITAL STAFF APPOINTMENTS:
Inova Fairfax Hospital
HONORS AND AWARDS:
Epilepsy Foundation/National Capitol Area
Washington Metropolitan Bioethics
MEDICAL STAFF POSITIONS & APPOINTMENTS:
Inova Alexandria Hospital
Inova Fairfax Hospital
Inova Health System
Reversible Mental Symptoms in Temporal Arteritis - Journal of Nervous and Mental Disorders, 166:446 1978.
Calcification Basal Ganglia, Neurology March 1979.
Transient Global Amnesia Following Cerebral Arteriography: Report of Seven Cases, Archives of Neurology, February 1983.
Transient Global Amnesia Associated with Migraine. Correspondence, Neurology, February 1983.
Transient Global Amnesia Following Cerebral Arteriography. Correspondence, Archives of Neurology, April 1983.
Monosodium Glutamania: The Chinese Restaurant Syndrome Revisited, JAMA, August 17, 1984 Volume 52, No. 7
Monosodium Glutamania vs Alcohol in the Chinese Restaurant Syndrome. Correspondence, JAMA, April 5, 1985 Volume 253, No. 13
Neurologic Disease: Five Scenarios to Manage in Patient Care, May 30, 1994, 32-51
"Restless Legs Syndrome", JAMA, January 17, 1996, Volume 275, No. 3
Series of Quarterly Columns "Ask Dr. Cochran" in the Newsletter of the Epilepsy Foundation National Capitol Area The Advocate 1989-1992 (Catamenial Epilepsy, Epilepsy Surgery, Alcohol and Epilepsy, Lifestyle and Epilepsy, Generic Medicine, Monotherapy)
Chapter Entitled Clinical Electrophysiology in Patient Care in Neurosurgery, Little Brown & Company, James R. Howe, M. D. 1983.
Poster Presentation, "Depakote in Clinical Outpatient Practice...Experience of 99 Consecutive Patients" given at The Practicing Physicians' Approach to the Difficult Headache Patient, Orlando, Florida, July 1998.
Poster Presentation, "Divalproex Sodium versus Tricyclic Agents in Migraine Prophylaxis: A Clinical Study comparing Efficacy and Tolerability" given at The Practicing Physicians' Approach to the Difficult Headache Patient, Orlando, Florida, July 1999.
Poster Presentation, "Concurrent Use of Sumatriptan and Naratriptan in Migraineurs with Recurrent Headache" given at The American Headache Society Meeting, Montreal, Canada, June 2000.
Poster Presentation, "Efficacy of Topiramate in Prophylactic Treatment of Migraine Headaches With and Without Aura: Open-Label Experience" given at The Practicing Physicians' Approach to the Difficult Headache Patient, Lake Buena Vista, Florida, July 2000.
Effect of Modafinil on Fatigue Associated with Neurologic Illness, Journal of Chronic Fatigue, Vol. 8(2) 2001 65-70
Poster Presentation, "Divalproex Sodium ER: Comparison to Divalproex Sodium" presented at Diamond Headache Meeting, Orlando, Florida, July 2001.
Poster Presentation, "Oxycarbazepine in Migraine Prophylaxis: A Pilot Study" presented at Diamond Headache Meeting, Orlando, Florida, July 2001.
Poster Presentation, "Incidence of Hyponatremia: 100 Consecutive Patients Treated With Antiepileptic Drugs" presented at Diamond Headache Meeting, Orlando, Florida, July 2001.
Poster Presentation, "Efficacy of Zonisamide in the Treatment of Neuropathic Pain " presented at American Pain Society, Baltimore, Maryland, March 2002.
Poster Presentation, "Efficacy of Zonisamide in Prophylactic Treatment of Migraine Headaches with or without Aura: Open-label Experience in 7 patients" presented at American Pain Society, Baltimore, Maryland, March 2002.
Poster Presentation, "Open-Label Experience in Patients with Migraine and Facial Pain: Efficacy of Zonisamide as Prophylaxis" presented at American Headache Society Annual Meeting, Seattle, Washington, June 2002.
Poster Presentation, "Clinical Experience With Vagal Nerve Stimulation and Excessive Daytime Sleepiness as Measured by the Epworth Sleepiness Scale" presented at APSS Annual Meeting, Seattle, Washington, June 2002.
Co-investigator: sumatriptan (subcutaneous) in acute migraine protocol 1990 (S2B-306)
Co-investigator: sumatriptan (oral) in acute migraine protocol 1990 (S2B-216)
Co-investigator: sumatriptan (oral) in migraine protocol 1991 (S2B-331)
Co-investigator: sumatriptan (oral and subcutaneous) in migraine protocol 1992 (S2B-310)
Principal Investigator: Carnitor and Sodium Valproate in patients with cognitive dysfunction, 1992.
Principal Investigator: DHE vs Sumatriptan in acute migraine 1993 (DHI-703)
Co-investigator: TIND, Safe use of Cognex/Tacrine (THA) 120 mg/day for patients with Alzheimer's Disease 1993.
Principal Investigator: rectal sumatriptan in migraine 1993 (S2B-353)
Co-investigator: TPA in acute stroke 1993.
Principal Investigator: intranasal DHE in familial migraine 1995 (DHE-45)
Co-investigator: STEPS, study of Neurontin: Titration to effect, profile of safety 1995.
Co-investigator: ALERT, Adjunctive Lamictal (Lamotrigine) in Epilepsy and Response to Treatment 1995.
Co-investigator: oral sumatriptan in adolescent migraine (SUMA-2002)
Principal Investigator: subcutaneous sumatriptan in the workplace for migraine (SUMA-4004)
Co-investigator: oral naratriptan in adolescent migraine 1995 (S2WA-3012)
Co-investigator: Baker Norton: Cervene: Modification of outcome in patients with acute ischemic stroke, a double-blind, randomized, placebo-controlled, parallel group, dose comparison study
Co-Investigator: Icos: Phase 2 Study of Hu23F2G in acute exacerbations of multiple sclerosis, 1997.
Co-Investigator: Algos: Morphine with Dextromethorphan
versus Morphine in cancer and other
Principal Investigator: Hoechst Marion Roussel Protocol VGPR00101: Efficacy of rational polytherapy with Sabril (Vigabatrin) monotherapy in the management of patients with non-refactory complex partial seizures. September 1995.
Co-Investigator: Wyeth-Ayerst Protocol 8997-A1-307-US and 897-A1-312-US: A double-blind safety, tolerance and efficacy study of Zaleplon in adult outpatients with insomnia. September 1995.
Principal Investigator: Cambridge Neuroscience Protocol CNS 1102-008: A multi-center, double-blind, placebo-controlled, dose-finding efficacy study of CNS 1102 in patients with acute cerebral ischemia. June 1995.
Principal Investigator: Parke-Davis Neurontin (STEPS) study for seizure. March 1995.
Principal Investigator: Burroughs-Wellcome Lamictal (ALERT) study for seizure. March 1995.
Principal Investigator: Lorex LES02 Protocol: Assessment of the Efficacy and Safety of Eliprodil in Patients with Acute Ischemic Stroke, June, 1996.
Principal Investigator: Knoll Pharmaceuticals Ancrod:
Parallel, Group Sequential Double-Blind,
Principal Investigator: Boehringer Ingelheim Inc: a Phase 2/3 multi-center, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of two doses of IV Aptiganel Hydrochloride versus placebo in patients with acute ischemic stroke, 1996.
Principal Investigator: Pfizer/Eisai: An open-label multi-center clinical trial evaluating the safety and efficacy of Donepezil HCL (E2020) in patients with Alzheimer's Disease, 1996.
Principal Investigator: Zeneca: A multi-center, double-blind, randomized comparison of Zolmitriptan and Sumatriptan in the acute treatment of multiple migraine headaches, 1997.
Principal Investigator: Novartis: An open-label study to evaluate the safety and efficacy of 1.5 mg BID of Exelon in patients with mild to severe probable Alzheimer's Disease in the community setting, 1997.
Principal Investigator: Eisai: A 24 week, multi-center, double-blind, placebo-controlled evaluation of the efficacy and safety of Donepezil Hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease, 1997.
Principal Investigator: Pozen: A single dose, double-blind, dose ranging, placebo-controlled safety and efficacy study of various doses of Naproxen Sodium and Metoclopramide in subjects with acute migraine headaches, 1997.
Principal Investigator: GlaxoWellcome: S2WA4003, A randomized double-blind, double dummy, active placebo-controlled, parallel group evaluation of oral Naratriptan (2.5 mg) compared to Oral Naproxen Sodium (275 mg) on Migraine related quality of life, 1997.
Sub Investigator: Icos Phase 2 Study of Hu23F2G in Acute Exacerbation of Multiple Sclerosis, 1997-98.
Principal Investigator: GlaxoWellcome: Open Randomized comparison of Add-on Lamotrigine or Valproate/Carbomazepine Withdrawing to Monotherapy in Patients With Treatment Resistant Epilepsy, 1998.
Sub-Investigator: Berlex: A Double-blind, placebo-controlled multi-center study to evaluate the efficacy and safety of 2 intended doses of intramuscular Phenoxybenzamine Hydrochloride Injection versus placebo in chronic muscle pain, 1998.
Principal Investigator: Parke-Davis: A 5 week, double-blind, placebo-controlled, parallel group study of pregabalin (I 50 and 450 mg/day) in patients with postherpetic neuralgia, 1998.
Principal Investigator: Abbott. The Safety and Efficacy of DivalProex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Double-Blind, Placebo-Controlled Study, 1998.
Sub-Investigator: Targon: A Multi-center, Randomized Double-Blind, Double-Dummy, Parallel Group Study of Morphelan in patients with chronic, moderate to severe pain, 1999.
Principal Investigator: Centaur: A 90 day Safety Study of CPI-1189 in male and female Parkinson's patients on L-Dopa plus Carbidopa, 1999.
Principal Investigator: Janssen: Placebo-controlled evaluation of galantamine in the treatment of Alzheimer's Disease, 1999.
Sub-Investigator: Parke-Davis: Pregabalin add-on trial: A randomized, double-blind, placebo-controlled study in patients with partial seizures, 1999.
Principal Investigator: Pfizer: A multi-center trial to evaluate the efficacy, tolerability and subject satisfaction with Eletriptan in the treatment of migraine headache attacks in Neurology practices, 1999.
Sub-investigator: R.W. Johnson: A randomized, double-blind, parallel group, monotherapy study to compare the safety and efficacy of two doses of Topiramate in the treatment of newly diagnosed or recurrent epilepsy, 1999.
Principal Investigator: R.W. Johnson: A double-blind, placebo-controlled, parallel group, dose response study to evaluate the efficacy and safety of topiramate versus placebo in the relief of pain in diabetic peripheral neuropathy, 1999.
Principal Investigator: GlaxoWellcome: An Open-label Evaluation of the Long-Term Safety or Oral Naratriptan 1 mg Twice Day as Short-Term Prophylactic Treatment for Menstrually-Associated Migraine, 2000.
Principal Investigator: Praecis Pharmaceuticals: A randomized, double-blind, parallel Group Study of the safety and efficacy of Latranal compared to Doxepin Cream and Placebo in patients with chronic low back pain, February 2001.
Principal Investigator: Novartis: Trileptal Diabetic Neuropathy Phase IV study, March 2001.
Principal Investigator: Janssen Research GAL-INT-26 Cerebral Vascular Dementia, August 2001.
Principal Investigator: AstraZeneca Zanadu Zomig ZMT: Open Label Comparison of the Effects of Zomig ZMT and Usual Migraine Care on Work Loss, Productivity, and Patient Preference December 2001.
Fairfax Office: 8505 Arlington Boulevard, Suite 450, Fairfax, Virginia 22031